SCNI Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2021–FY2025
Scinai Immunotherapeutics Ltd. had only $1.3M of revenue in fiscal 2025: it is still developing what it sells. It spent $2.4M on research and development, 27% of its operating costs.
Last close · Oct 30, 2026
$0.47
−$14.13 (−96.77%) past year
Hi! I read Scinai Immunotherapeutics Ltd.’s latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are shareholders being diluted?
+189.6%
A lot. The share count rose 189.6% last year, so each share owns noticeably less.
Does it make a profit?
$2.4M R&D
Not yet: it has no meaningful sales. It spent $2.4M on research and development, 27% of its operating costs.
How long would its cash last?
0.3 yrs
Not long. It burns $6.1M a year and holds $1.7M, under a year at that pace, so it may need new money soon.
How healthy are the accounts?
2 / 8
It passes 2 of 8 health tests, but most of them need sales, so the score says little before revenue starts.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA summarises the numbers
Scinai Immunotherapeutics Ltd. had only $1.3M of revenue in fiscal 2025: it is still developing what it sells.
It spent $2.4M on research and development, 27% of its operating costs.
Its operating margin was −575.3%, up 737.5 pts: of every 100 in sales, about −575 is left after running the business.
Revenue
Margins, % of revenue
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Loss periods are shown in red.
KIRA summarises the numbers
Scinai Immunotherapeutics Ltd. lost $8.3M in fiscal 2025.
With no meaningful sales yet, it pays for its work from the cash it holds.
Net income
Net income
Diluted EPS
Diluted EPS
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
KIRA summarises the numbers
Free cash flow was −$6.1M in fiscal 2025, −461.9% of revenue.
At that burn of $6.1M a year, its $1.7M of cash and short-term investments would last about 0.3 years.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends and buybacks
Diluted shares outstanding (annual)
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
No open-market insider trades in the last 12 months.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Scinai Immunotherapeutics Ltd. can carry it.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $17.4M | $14.1M | $4.9M | $2.0M | $1.7M |
| Debt incl. finance leases | $0.4M | $0.4M | — | — | — |
| Debt / equity | 0.4x | — | — | — | — |
| Interest coverage | −32.3x | −31.5x | −28.3x | — | — |
| Current ratio | 7.3x | 6.1x | 3.1x | 1.3x | 1.3x |
| Quick ratio | 7.3x | 6.1x | 3.1x | 1.3x | 1.3x |
| Total assets | $32.0M | $27.1M | $17.5M | $13.4M | $11.6M |
| Total liabilities | $31.1M | $28.8M | $22.0M | $3.5M | $3.5M |
| Shareholders' equity | $1.0M | −$1.8M | −$4.6M | $10.0M | $8.1M |
| Net debt (− = net cash) | −$17.0M | −$13.7M | — | — | — |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
KIRA summarises the numbers
Scinai Immunotherapeutics Ltd. passes 2 of 8 financial health tests (Piotroski F-score).
Most of these tests look at sales and margins, so the score says little about a company with no meaningful revenue yet.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| F-score | — / 3 | 1 / 7 | — / 6 | — / 6 | 2 / 8 |
| Accruals ratio | −2.4% | 5.0% | 12.9% | 72.0% | −18.2% |
| Altman Z'' | −10.29 | −13.85 | −25.40 | −29.51 | −36.97 |
| Net income is positive | ✕ | ✕ | ✕ | ✓ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✕ | ✓ | ✕ |
| Cash from operations exceeds net income | ✓ | ✕ | ✕ | ✕ | ✓ |
| Debt fell relative to assets | — | ✕ | — | — | — |
| Current ratio rose | — | ✕ | ✕ | ✕ | ✕ |
| Share count didn't rise | — | ✕ | ✕ | ✕ | ✕ |
| Gross margin rose | — | — | — | — | ✕ |
| Revenue rose relative to assets | — | — | — | — | ✓ |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
Every number, year by year.
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $0.7M | $1.3M |
| Gross profit | — | — | — | −$0.6M | −$2.7M |
| Research and development | $3.2M | $5.8M | $5.2M | $5.5M | $2.4M |
| Operating income | −$10.9M | −$11.1M | −$9.7M | −$8.6M | −$7.5M |
| Interest expense | $0.3M | $0.4M | $0.3M | — | — |
| Net income | −$8.2M | −$5.8M | −$6.5M | $4.8M | −$8.3M |
| Net income to common | $8.2M | $5.8M | $6.5M | — | — |
| Diluted EPS | −$0.02 | $0.01 | $0.00 | — | — |
| Diluted shares | 0.56B | 0.75B | 1.56B | 3.23B | 9.34B |
| Cash flow | |||||
| Cash from operations | −$7.4M | −$7.3M | −$9.4M | −$6.3M | −$6.0M |
| Capital expenditure | $0.1M | $0.8M | $0.6M | $0.0M | $0.0M |
| Free cash flow | −$7.6M | −$8.1M | −$10.0M | −$6.3M | −$6.1M |
| Depreciation and amortization | $0.5M | $0.6M | $0.5M | $1.6M | $1.4M |
| Stock-based compensation | $2.8M | $1.6M | $1.1M | $0.7M | $0.3M |
| Balance sheet | |||||
| Cash and short-term investments | $17.4M | $14.1M | $4.9M | $2.0M | $1.7M |
| Total debt | $0.4M | $0.4M | — | — | — |
| Current assets | $17.8M | $14.4M | $5.4M | $2.4M | $2.1M |
| Current liabilities | $2.4M | $2.3M | $1.8M | $1.8M | $1.6M |
| Property and equipment, net | $12.4M | $11.2M | $10.8M | $9.2M | $7.8M |
| Total assets | $32.0M | $27.1M | $17.5M | $13.4M | $11.6M |
| Total liabilities | $31.1M | $28.8M | $22.0M | $3.5M | $3.5M |
| Preferred stock | — | — | — | $5.6M | $5.6M |
| Shareholders' equity | $1.0M | −$1.8M | −$4.6M | $10.0M | $8.1M |
| Margins | |||||
| Gross margin | — | — | — | −88.1% | −202.3% |
| Operating margin | — | — | — | −1,312.8% | −575.3% |
| EBITDA margin | — | — | — | −1,062.2% | −466.9% |
| Net margin | — | — | — | 728.9% | −633.6% |
| FCF margin | — | — | — | −964.6% | −461.9% |
| Returns | |||||
| Return on capital employed | −36.7% | −44.7% | −61.9% | −74.2% | −75.1% |
| Return on equity | −835.6% | — | — | 177.4% | −91.9% |
| Return on assets | −25.6% | −19.6% | −29.2% | 31.0% | −66.3% |
| Return on tangible equity | 835.6% | — | — | 48.1% | −102.5% |
| Growth | |||||
| Revenue growth | — | — | — | — | 99.2% |
| Net income growth | — | — | — | — | −273.2% |
| EPS growth | — | — | −60.0% | — | — |
| Share count change | — | 33.6% | 107.2% | 106.4% | 189.6% |
| Financial health | |||||
| Debt / equity | 0.4x | — | — | — | — |
| Interest coverage | −32.3x | −31.5x | −28.3x | — | — |
| Current ratio | 7.3x | 6.1x | 3.1x | 1.3x | 1.3x |
| Quick ratio | 7.3x | 6.1x | 3.1x | 1.3x | 1.3x |
| Capital allocation | |||||
| Capex / revenue | — | — | — | 1.8% | 1.8% |
| Stock comp / revenue | — | — | — | 103.6% | 23.1% |
| Quality scores | |||||
| Piotroski F-score | — | 1.0 | — | — | 2.0 |
| Altman Z'' | −10.3 | −13.8 | −25.4 | −29.5 | −37.0 |
| Accruals ratio | −2.4% | 5.0% | 12.9% | 72.0% | −18.2% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
The original documents every number on this page comes from.
Source: SEC EDGAR XBRL filings (CIK 0001611747). Data updated November 1, 2026. Quarterly fourth quarters are the full year minus the first nine months. The ADS ratio could not be read from the filing, so market cap and valuation are not shown. For information only — not investment advice. Check the original filings before relying on any figure.
Do you want to get alerts?
An email when your companies or sectors make a big move at the close. Free, and you leave with one click.
Do you want to turn on or review your alerts?
Add companies or sectors, change the move that triggers an email, or pause what you no longer need.
We would like to use Google Analytics and Amplitude cookies to count visits and see how pages are used, including anonymised session recordings, so we can improve Stoqly. They are only set if you accept. No ads, no selling of data. Cookie policy
